The growing burden of metabolic disorders manifested by hypertension, type 2 diabetes mellitus, hyperlipidemia, obesity and non-alcoholic fatty liver disease presents a significant global health challenge by contributing to cardiovascular diseases and high mortality rates. Β-blockers are among the most widely used drugs in the treatment of hypertension and acute cardiovascular events. In addition to blocking the receptor sites for catecholamines, third-generation β-blockers with associated vasodilating properties, such as carvedilol and nebivolol, provide a broad spectrum of metabolic effects, including anti-inflammatory and antioxidant properties and a favorable impact on glucose and lipid metabolism. This review aims to report the impact of β-blockers on metabolic modulation based on available literature data. We present an overview of β-blockers and their pleiotropic properties, discuss mechanisms by which these drugs affect cellular metabolism and outline the future perspectives. The influence of β-blockers on glucose metabolism, insulin sensitivity, inflammation and oxidative stress is complex and varies depending on the specific β-blocker used, patient population and underlying health conditions. Recent evidence particularly highlights the potential role of vasodilatory and nitric oxide-mediated properties of nebivolol and carvedilol in improving glycemic control, insulin sensitivity, and lipid metabolism and mitigating oxidative stress and inflammation. It suggests that these drugs may be potential therapeutic options for patients with metabolic disorders, extending beyond their primary role in cardiovascular management.
Glycation is defined as a non-enzymatic reaction wherein reducing sugars interact with amino acid residues present in proteins, resulting in the formation of advanced glycation end-products (AGE). This biochemical phenomenon is linked to several pathological conditions, particularly cardiovascular disease (CVD) and diabetes, as it significantly contributes to the onset of endothelial dysfunction and inflammation. Given these connections, vasodilatory β-blockers (VBB) have garnered interest due to their multifaceted pharmacological effects that extend beyond traditional β-adrenergic blockade. These agents not only enhance endothelial function but also exhibit notable antioxidant and anti-inflammatory properties, which may be associated with their capacity to inhibit glycation processes. In our study, we examined these properties through an in vitro and in silico study utilizing bovine serum albumin (BSA) as a model with multiple carbohydrates and aldehydes as glycation agents. Furthermore, we evaluated the binding affinity of VBB to BSA and pro-inflammatory proteins via molecular docking. The results indicated that while VBB were effective in diminishing the rates of protein glycation their effectiveness was generally lower than that of aminoguanidine, a recognized anti-glycation agent. In contrast, molecular docking analyses suggested that the anti-inflammatory properties of VBB may be due to their competition with glycation agents for binding sites on BSA, as well as their interactions with proteins integral to the activation of pro-inflammatory signaling pathways.
Allergies and diabetes mellitus are highly prevalent, frequently co-occurring diseases. Antihistamines, the first-line treatment for allergies, block H1 receptors but also exhibit anti-inflammatory and antioxidant properties that may improve glucose metabolism. This systematic review examined the evidence for the potential antidiabetic effects of commonly used first- and second-generation antihistamines. A comprehensive search of the PubMed database (1978–May 2026) yielded 17 eligible in vivo, in vitro, clinical, and in silico studies. Most reports indicated that antihistamines improve glucose tolerance, insulin sensitivity, and insulin secretion. Proposed mechanisms include enhanced insulin release, mast cell stabilization, attenuation of immune-mediated responses, reduced nephron alteration, and improved incretin signalling. Although substantial heterogeneity in study designs limits direct comparisons, current evidence suggests a beneficial role of antihistamines in modulating glucose metabolism, particularly for patients managing both allergies and diabetes. These findings highlight the potential for drug repurposing. However, further well-designed clinical trials are required to ensure reproducibility, successful animal-to-human translation, and overall safety before clinical implementation.